Contract facts
UnrestrictedBIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Bioaegis Therapeutics Inc. Estimated value $20M ($20M obligated). Current period of performance ends Aug 31, 2027. Last award drew 100 bidders. Place of performance: MORRISTOWN NJ.
BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I
Recompete timing
PublicCurrent PoP ends Aug 31, 2027 (338 days remaining). Agencies typically plan 12–18 months ahead — at 11.1 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75A50123C00067? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordBioaegis Therapeutics Inc — $20.0M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50123C00067?
75A50123C00067 (PGSN PGSN and) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $20M, currently held by Bioaegis Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50123C00067?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50123C00067 to Bioaegis Therapeutics Inc (potential $20M).
Who is the incumbent on 75A50123C00067?
Bioaegis Therapeutics Inc is the incumbent with $20.0M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2027.
When does Bioaegis Therapeutics Inc’s 75A50123C00067 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50123C00067? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.